Antihypertensive effect of valyl-tyrosine, a short chain peptide derived from sardine muscle hydrolyzate, on mild hypertensive subjects

T. Kawasaki, E. Seki, K. Osajima, M. Yoshida, K. Asada, T. Matsui, Y. Osajima

Research output: Contribution to journalArticle

182 Citations (Scopus)

Abstract

The present study was conducted to determine whether Valyl-Tyrosine (VY) has an antihypertensive effect on high-normal blood pressure and mild essential hypertension, as well as spontaneous hypertensive rats (SHR). A randomised double-blind placebo-controlled study was carried out on 29 volunteers. A 100-ml drink containing 3 mg of VY and a 100-ml placebo drink were prepared. The subjects were grouped as VY(16M/1F, 45.5 ± 3.2 years, 146.4 ± 2.3/90.5 ± 1.8 mm Hg) and the placebo (P) (11 M/1F, 48.8 ± 3.0 years, 145.5 ± 2.4/92.3 ± 1.8 mm Hg). At 3 weeks of the control (C) period, a VY- or P-drink was administered twice a day for 4 weeks in the experimental (E) period and during the 4-week recovery period, neither drink was given to either group. Blood pressure (BP) was measured every week in the morning in the sitting position. Blood specimens were taken on the last day of the C and E periods. In the VY-group, reduction in systolic (S) and diastolic (D) BP was 9.7 and 5.3 mm Hg (P < 0.001) at 1 week, and 9.3 and 5.2 mm Hg (P < 0.001) at 4 weeks, following the start of the E period, respectively. Neither SBP nor DBP changed in the P-group. BP in the VY-group increased gradually by the end of the recovery period. Plasma angiotensin (Ang) I and VY concentrations significantly increased while Ang II and aldosterone significantly decreased after VY administration in the VY-group. VY appeared to have a significant antihypertensive effect on mild hypertensive subjects via Ang I-converting enzyme inhibition, as well as SHR, but no adverse effects could be detected at all.

Original languageEnglish
Pages (from-to)519-523
Number of pages5
JournalJournal of human hypertension
Volume14
Issue number8
DOIs
Publication statusPublished - Jan 1 2000

Fingerprint

valyltyrosine
Antihypertensive Agents
Muscles
Peptides
Placebos
Blood Pressure
Angiotensin I
Peptidyl-Dipeptidase A
Aldosterone
Posture
Angiotensin II

All Science Journal Classification (ASJC) codes

  • Internal Medicine

Cite this

Antihypertensive effect of valyl-tyrosine, a short chain peptide derived from sardine muscle hydrolyzate, on mild hypertensive subjects. / Kawasaki, T.; Seki, E.; Osajima, K.; Yoshida, M.; Asada, K.; Matsui, T.; Osajima, Y.

In: Journal of human hypertension, Vol. 14, No. 8, 01.01.2000, p. 519-523.

Research output: Contribution to journalArticle

Kawasaki, T. ; Seki, E. ; Osajima, K. ; Yoshida, M. ; Asada, K. ; Matsui, T. ; Osajima, Y. / Antihypertensive effect of valyl-tyrosine, a short chain peptide derived from sardine muscle hydrolyzate, on mild hypertensive subjects. In: Journal of human hypertension. 2000 ; Vol. 14, No. 8. pp. 519-523.
@article{32e147c211b047bb9dc7de05dea86da7,
title = "Antihypertensive effect of valyl-tyrosine, a short chain peptide derived from sardine muscle hydrolyzate, on mild hypertensive subjects",
abstract = "The present study was conducted to determine whether Valyl-Tyrosine (VY) has an antihypertensive effect on high-normal blood pressure and mild essential hypertension, as well as spontaneous hypertensive rats (SHR). A randomised double-blind placebo-controlled study was carried out on 29 volunteers. A 100-ml drink containing 3 mg of VY and a 100-ml placebo drink were prepared. The subjects were grouped as VY(16M/1F, 45.5 ± 3.2 years, 146.4 ± 2.3/90.5 ± 1.8 mm Hg) and the placebo (P) (11 M/1F, 48.8 ± 3.0 years, 145.5 ± 2.4/92.3 ± 1.8 mm Hg). At 3 weeks of the control (C) period, a VY- or P-drink was administered twice a day for 4 weeks in the experimental (E) period and during the 4-week recovery period, neither drink was given to either group. Blood pressure (BP) was measured every week in the morning in the sitting position. Blood specimens were taken on the last day of the C and E periods. In the VY-group, reduction in systolic (S) and diastolic (D) BP was 9.7 and 5.3 mm Hg (P < 0.001) at 1 week, and 9.3 and 5.2 mm Hg (P < 0.001) at 4 weeks, following the start of the E period, respectively. Neither SBP nor DBP changed in the P-group. BP in the VY-group increased gradually by the end of the recovery period. Plasma angiotensin (Ang) I and VY concentrations significantly increased while Ang II and aldosterone significantly decreased after VY administration in the VY-group. VY appeared to have a significant antihypertensive effect on mild hypertensive subjects via Ang I-converting enzyme inhibition, as well as SHR, but no adverse effects could be detected at all.",
author = "T. Kawasaki and E. Seki and K. Osajima and M. Yoshida and K. Asada and T. Matsui and Y. Osajima",
year = "2000",
month = "1",
day = "1",
doi = "10.1038/sj.jhh.1001065",
language = "English",
volume = "14",
pages = "519--523",
journal = "Journal of Human Hypertension",
issn = "0950-9240",
publisher = "Nature Publishing Group",
number = "8",

}

TY - JOUR

T1 - Antihypertensive effect of valyl-tyrosine, a short chain peptide derived from sardine muscle hydrolyzate, on mild hypertensive subjects

AU - Kawasaki, T.

AU - Seki, E.

AU - Osajima, K.

AU - Yoshida, M.

AU - Asada, K.

AU - Matsui, T.

AU - Osajima, Y.

PY - 2000/1/1

Y1 - 2000/1/1

N2 - The present study was conducted to determine whether Valyl-Tyrosine (VY) has an antihypertensive effect on high-normal blood pressure and mild essential hypertension, as well as spontaneous hypertensive rats (SHR). A randomised double-blind placebo-controlled study was carried out on 29 volunteers. A 100-ml drink containing 3 mg of VY and a 100-ml placebo drink were prepared. The subjects were grouped as VY(16M/1F, 45.5 ± 3.2 years, 146.4 ± 2.3/90.5 ± 1.8 mm Hg) and the placebo (P) (11 M/1F, 48.8 ± 3.0 years, 145.5 ± 2.4/92.3 ± 1.8 mm Hg). At 3 weeks of the control (C) period, a VY- or P-drink was administered twice a day for 4 weeks in the experimental (E) period and during the 4-week recovery period, neither drink was given to either group. Blood pressure (BP) was measured every week in the morning in the sitting position. Blood specimens were taken on the last day of the C and E periods. In the VY-group, reduction in systolic (S) and diastolic (D) BP was 9.7 and 5.3 mm Hg (P < 0.001) at 1 week, and 9.3 and 5.2 mm Hg (P < 0.001) at 4 weeks, following the start of the E period, respectively. Neither SBP nor DBP changed in the P-group. BP in the VY-group increased gradually by the end of the recovery period. Plasma angiotensin (Ang) I and VY concentrations significantly increased while Ang II and aldosterone significantly decreased after VY administration in the VY-group. VY appeared to have a significant antihypertensive effect on mild hypertensive subjects via Ang I-converting enzyme inhibition, as well as SHR, but no adverse effects could be detected at all.

AB - The present study was conducted to determine whether Valyl-Tyrosine (VY) has an antihypertensive effect on high-normal blood pressure and mild essential hypertension, as well as spontaneous hypertensive rats (SHR). A randomised double-blind placebo-controlled study was carried out on 29 volunteers. A 100-ml drink containing 3 mg of VY and a 100-ml placebo drink were prepared. The subjects were grouped as VY(16M/1F, 45.5 ± 3.2 years, 146.4 ± 2.3/90.5 ± 1.8 mm Hg) and the placebo (P) (11 M/1F, 48.8 ± 3.0 years, 145.5 ± 2.4/92.3 ± 1.8 mm Hg). At 3 weeks of the control (C) period, a VY- or P-drink was administered twice a day for 4 weeks in the experimental (E) period and during the 4-week recovery period, neither drink was given to either group. Blood pressure (BP) was measured every week in the morning in the sitting position. Blood specimens were taken on the last day of the C and E periods. In the VY-group, reduction in systolic (S) and diastolic (D) BP was 9.7 and 5.3 mm Hg (P < 0.001) at 1 week, and 9.3 and 5.2 mm Hg (P < 0.001) at 4 weeks, following the start of the E period, respectively. Neither SBP nor DBP changed in the P-group. BP in the VY-group increased gradually by the end of the recovery period. Plasma angiotensin (Ang) I and VY concentrations significantly increased while Ang II and aldosterone significantly decreased after VY administration in the VY-group. VY appeared to have a significant antihypertensive effect on mild hypertensive subjects via Ang I-converting enzyme inhibition, as well as SHR, but no adverse effects could be detected at all.

UR - http://www.scopus.com/inward/record.url?scp=0033839717&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033839717&partnerID=8YFLogxK

U2 - 10.1038/sj.jhh.1001065

DO - 10.1038/sj.jhh.1001065

M3 - Article

C2 - 10962520

AN - SCOPUS:0033839717

VL - 14

SP - 519

EP - 523

JO - Journal of Human Hypertension

JF - Journal of Human Hypertension

SN - 0950-9240

IS - 8

ER -